(2-甲基吡啶-3-基)氨基甲酸叔丁酯 | 1219095-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (2-甲基吡啶-3-基)氨基甲酸叔丁酯
• 英文名称: tert-butyl N-(2-methylpyridin-3-yl)carbamate
• 英文别名: tert-butyl N-(2-methyl-3-pyridyl)carbamate；N-Boc-3-amino-2-methylpyridine；tert-butyl (2-methylpyridin-3-yl)carbamate
• CAS: 1219095-87-0
• 化学式: C₁₁H₁₆N₂O₂
• mdl: MFCD17169891
• 分子量: 208.26
• InChiKey: RQLNGFJNDOYANP-UHFFFAOYSA-N

物化性质

• 沸点：
  257.6±28.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  (2-甲基吡啶-3-基)氨基甲酸叔丁酯 在 盐酸 、 platinum(IV) oxide 、 氢气 、 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~90.0 ℃ 、405.33 kPa 条件下， 反应 8.0h， 生成 5-[(2R,3R)-3-amino-2-methylpiperidin-1-yl]-3-[(3-methyl-1,2-thiazol-5-yl)amino]pyridine-2-carbonitrile
  参考文献：
  名称：

  [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE
  [FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON

  摘要：

  公开号：

  WO2016196776A3
• 作为产物：
  描述：

  氨基甲酸叔丁酯 、 2-甲基-3-溴吡啶 在 palladium diacetate 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以62%的产率得到(2-甲基吡啶-3-基)氨基甲酸叔丁酯
  参考文献：
  名称：

  Pd-catalyzed amidation of aryl(Het) halides with tert-butyl carbamate

  摘要：

  Pd-catalyzed cross-coupling reaction of tert-butyl carbamate with various aiyl(Het) halides with Cs(2)CO(3) as base in 1.4-dioxane as solvent was investigated, which resulted in the formation of the desired compounds in moderate to excellent yields (C) 2010 Elsevier Ltd All rights reserved

  DOI：

  10.1016/j.tetlet.2010.06.083

文献信息

• [EN] BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS PYRIDAZINES BICYCLIQUES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2012148775A1

  公开（公告）日：2012-11-01

  The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式I和I'的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文披露的化合物的药物组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症中的应用。
• [EN] PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS PYRROLO[2,3-B]PYRIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2019034890A1

  公开（公告）日：2019-02-21

  The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

  本申请涉及公式I的化合物，或其盐、水合物或溶剂合物，如本文所定义。发现这些化合物具有药理效应，特别是在MRCK上。还提供包含这些化合物的药物组合物。本发明还涉及将这些化合物用作治疗剂，特别是用于治疗和/或预防增殖性疾病，如癌症。
• Bicyclic Pyridazine Compounds as PIM Inhibitors
  申请人：D'amico Derin C.

  公开号：US20140221344A1

  公开（公告）日：2014-08-07

  The invention relates to bicyclic compounds of formulas I and I′, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及式I和I'的双环化合物及其盐。在某些实施例中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含所述化合物的制药组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症方面的应用。
• Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
  申请人：Cancer Research Technology Limited

  公开号：US11447505B1

  公开（公告）日：2022-09-20

  The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

  本申请涉及如本文所定义的式 I 化合物或其盐、水合物或溶液。发现本化合物具有药理作用，特别是在 MRCK 方面。本发明还提供了包含上述化合物的药物组合物。本发明还涉及将这些化合物用作治疗剂，特别是用于治疗和/或预防癌症等增殖性疾病。
• Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors
  作者：Ryan P. Wurz、Christine Sastri、Derin C. D’Amico、Brad Herberich、Claire L.M. Jackson、Liping H. Pettus、Andrew S. Tasker、Bin Wu、Nadia Guerrero、J. Russell Lipford、Jeffrey T. Winston、Yajing Yang、Paul Wang、Yen Nguyen、Kristin L. Andrews、Xin Huang、Matthew R. Lee、Christopher Mohr、J.D. Zhang、Darren L. Reid、Yang Xu、Yihong Zhou、Hui-Ling Wang

  DOI：10.1016/j.bmcl.2016.09.067

  日期：2016.11

  High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit (rac-1) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound 22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50 values of 0.024 nM and 0.095 nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50 = 28 nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound 22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication. (C) 2016 Elsevier Ltd. All rights reserved.